Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 3
2005 pubmed

Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids.

Barańska-Rybak. W W; Sonesson. A A; Nowicki. R R; Schmidtchen. A A

Key Findings

  • High glycosaminoglycan levels in wound fluids and plasma strongly reduce LL‑37’s antibacterial activity.
  • Heparin‑treated plasma also blocks LL‑37, confirming the role of GAGs as inhibitors.
  • Cationic polymers such as DEAE‑dextran and chitosan bind GAGs and restore LL‑37’s ability to kill bacteria.

Practical Outcomes

  • If you’re using LL‑37‑based or peptide‑rich skin products, be aware that GAG‑rich fluids may blunt their effect. Adding a safe polycation like chitosan (e.g., in a dressing or topical gel) could boost antimicrobial action in wounds. This insight is mainly useful for designing wound‑care formulations rather than direct dosing advice.

Summary

The study shows that natural sugars called glycosaminoglycans (found in wound fluid, plasma, and serum) can block the infection‑killing action of the human peptide LL‑37, but positively charged substances like chitosan can free LL‑37 and make it work better again.

Abstract

The antibacterial activity of antimicrobial peptides is influenced by various factors such as salt content, pH and the presence of proteins. In this study, we explored the antibacterial action of the human cathelicidin LL-37 in physiologically relevant conditions, i.e. various human wound fluids, human plasma fractions and serum. Radial diffusion assays using Staphylococcus aureus and Escherichia coli were employed for the study of antibacterial effects of LL-37 in the presence of 12 different wound fluids, citrate-, heparin- or EDTA-plasma, or human serum. Glycosaminoglycan content of wound fluids was determined by an Alcian Blue-binding assay. Protein content of wound fluids was measured by the Bradford method. A slot-binding assay was used to study the effects of inhibitors on the interaction between LL-37 and glycosaminoglycans. Five of twelve wound fluids derived from acute wounds showed marked inhibitory effects on the antibacterial action of LL-37. The inhibition was significantly correlated with high glycosaminoglycan content in wound fluid. Analogous to these findings, heparin-plasma strongly inhibited the antibacterial effect of LL-37. The interaction between LL-37 and glycosaminoglycans was abrogated by the cationic polymers DEAE-dextran and chitosan, yielding increased activity of LL-37. Glycosaminoglycan-rich biological fluids inhibit the antibacterial effects of LL-37. Furthermore, polycations that bind to glycosaminoglycans increase the antibacterial activities of endogenous antimicrobial peptides in glycosaminoglycan-containing biological fluids.

Study Information

Provider

pubmed

Year

2005

Date

2005-12-30T00:00:00.000Z

DOI

10.1093/jac/dki460